Skip To Main Content
Maryou B.K. Lambros on Muck Rack

Maryou B.K. Lambros

As seen in: Cell Press, European Urology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Maryou B.K.

Contact Maryou B.K., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Elucidating acquired PARP inhibitor resistance in advanced prostate cancer

|
By George Seed, Nick Beije, Wei Yuan, Claudia Bertan, Jane Goodall, Arian Lundberg, Matthew Tyler, Inês André Figueiredo, Rita Pereira, Chloe Baker, Denisa Bogdan, Lewis Gallagher, Jan-Phillipp Cieslik, Semini Greening, Maryou B.K. Lambros, Rui Neves, Lorena Magraner-Pardo, Gemma Fowler, Berni Ebbs, Susana Miranda, Penny Flohr, Diletta Bianchini, Pasquale Rescigno, Nuria Porta, Emma Hall Verified, Bora Gurel, Nina Tunariu, Adam Sharp, Stephen Pettit, Nikolas H. Stoecklein, Shahneen Sandhu, David Quigley Verified, Christopher Lord Verified, Joaquin Mateo, Suzanne Carreira, Johann De Bono
| Cell Press Verified
Keywords DNA repair prostate cancer genomics cfDNA PARP inhibition reversion Introduction Prostate cancer is the second most diagnosed cancer in men globally and is responsible for significant cancer-related mortality.1 The treatment of metastatic castration-resistant prostate cancer (mCRPC) has been transformed with the introduction of poly(ADP-ribose)-polymerase inhibition (PARPi), with phase 3 trials demonstrating survival benefit in mCRPC harboring DNA repair defects including BRCA2 or...
Open in Who Shared Issue with article?

Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer

|
By Adam Sharp, Jon C. Welti, Maryou B.K. Lambros, David Dolling
| European Urology Verified
1. Introduction Prostate cancer (PC) is the most common malignancy and the second leading cause of cancer-related death in men in the Western world [1x[1]Siegel, R., Naishadham, D., and Jemal, A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11–30 Google ScholarSee all References][1].
Open in Who Shared Issue with article?
See all 2 articles